Zanzalintinib is a small molecule commercialized by Exelixis, with a leading Phase III program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 6 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Zanzalintinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Zanzalintinib is expected to reach an annual total of $672 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Zanzalintinib Overview

Zanzalintinib fumarate (XL-092) is under development for the treatment of solid tumors such as metastatic renal cell carcinoma, metastatic urothelial carcinoma including the renal pelvis, ureter, urinary bladder, urethra cancer, metastatic castration resistant prostate cancer, metastatic hepatocellular carcinoma, papillary renal cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer and human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer). The drug candidate is administered through oral route. It acts by targeting protein tyrosine kinases which constitutes of MET, VEGFR, AXL and MER, TYRO3.

It was under development for the treatment of non-small cell lung cancer.

Exelixis Overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
The company reported revenues of (US Dollars) US$1,830.2 million for the fiscal year ended December 2023 (FY2023), an increase of 13.6% over FY2022. In FY2023, the company’s operating margin was 9.3%, compared to an operating margin of 12.5% in FY2022. In FY2023, the company recorded a net margin of 11.4%, compared to a net margin of 11.3% in FY2022.

For a complete picture of Zanzalintinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.